亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

(S)-(+)-3-羥基四氫呋喃

 
 
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 09:59
 

濟南惠誠醫藥科技有限公司

企業會員第10年
資料未認證
保證金未繳納
詳細說明

中文名稱: (S)-(+)-3-羥基四氫呋喃

中文同義詞: (S)-(+)-3-羥基四氫呋喃;S(+)-3-羥基四氫呋喃;(S)-(+)3-羥基-四氫呋喃;S-3-羥基四氫呋喃;(S)-(+)-羥基四氫呋喃;S-3-羥基四氫呋喃(阿法替尼中間體);阿法替尼中間體 B;(S)-(+)-3-羥基四氫呋喃, EE

英文名稱: (S)-(+)-3-Hydroxytetrahydrofuran

英文同義詞: (S)-TETRAHYDROFURAN-3-OL;(S)-(+)-TETRAHYDRO-3-FURANOL;(S)-(+)-3-HYDROXY TETAHYDRO FURAN;(S)-(-)-3-HYDROXY TETRAHYDRO FURAN;(S)-(+)-3-HYDROXYTETRAHYDROFURAN;(S)-3-HYDROXYTETRAHYDROFURAN;(S)-(+)-3-HYDROXYTETRAHYDROFURANE;3-FURANOL, TETRAHYDRO-, (S)

CAS: 86087-23-2

分子式: C4H8O2

分子量: 88.11

相關類別: Alcohols, Hydroxy Esters and Derivatives;Chiral *pounds;Starting Raw Materials & Intermediates;Small molecule;Tetrahydrofuran Series;四氫呋喃系列;Chiral Reagents;Furans;呋喃類;Chiral Building Blocks;Simple Alcohols (Chiral);Synthetic Organic Chemistry;呋喃;醫藥中間體;中間體;雜環砌塊;Afatinib intermediate;阿法替尼 中間體;阿法替尼與安普那韋共用中間體;通用試劑;阿法替尼中間體;抗癌類;恩格列凈中間體一

用途:阿法替尼與安普那韋共用中間體,恩格列凈中間體。

舉報收藏 0評論 0
更多>本企業其它產品
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |